Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients

Hepatology

Volumn 44, Issue 3, 2006, Pages 694-702

  Laras, Andreas ^a   Koskinas, John ^a   Dimou, Evangelini ^a,b   Kostamena, Ageliki ^a   Hadziyannis, Stephanos J ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DNA REPLICATION; DNA VIRUS; FEMALE; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; MALE; MUTANT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIRUS DETECTION; VIRUS INFECTION; VIRUS REPLICATION;

ADOLESCENT; ADULT; AGED; DNA, CIRCULAR; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SEVERITY OF ILLNESS INDEX; VIRUS REPLICATION;

EID: 33748939050     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21299     Document Type: Article

References (44)

1. Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1995;1:7-36.
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-1745.
3. Lok AS, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2001;34:1225-1241.
4. Nassal M, Schaller H. Hepatitis B virus replication-an update. J Viral Hepat 1996;3:217-226.
5. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000;64:51-68.
6. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982;29:403-415.
7. Bock CT, Schranz P, Schroder CH, Zentgraf H. Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes 1994;8:215-229.
8. Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, et al. The covalently dosed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 1995;69:3350-3357.
9. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986;47:451-460.
10. Kramvis A, Kew MC. The core promoter of hepatitis B virus. J Viral Hepat 1999;6:415-427.
11. Yaginuma K, Shirakata Y, Kobayashi M, Koike K. Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA. Proc Natl Acad Sci U S A 1987;84:2678-2682.
12. Will H, Reiser W, Weimer T, Pfaff E, Buscher M, Sprengel R, et al. Replication strategy of human hepatitis B virus. J Virol 1987;61:904-911.
13. Takahashi K, Kishimoto S, Ohori K, Yoshizawa H, Machida A, Ohnuma H, et al. Molecular heterogeneity of e antigen polypeptides in sera from carriers of hepatitis B virus. J Immunol 1991;147:3156-3160.
14. Wu TT, Coates L, Aldrich CE, Summers J, Mason WS. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 1990;175:255-261.
15. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989;2:588-591.
16. Gunther S, Fischer L, Pult I, Sterneck M, Will H. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999;52:25-137.
17. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. HEPATOLOGY 2000;31:1037-1044.
18. Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated pre-core and core promoter variants. J Viral Hepat 2002;9:52-61.
19. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. HEPATOLOGY 2001;34:617-624.
20. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996;70:5845-5851.
21. Gunther S, Piwon N, Will H. Wild-type levels of pregenomic RNA and replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B virus with C(1653) → T, A(1762) → T and G(1764) → A mutations in the core promoter. J Gen Virol 1998;79(Pt 2):375-380.
22. Laras A, Koskinas J, Hadziyannis SJ. In vivo suppression of precore mRNA synthesis is associated with mutations in the hepatitis B virus core promoter. Virology 2002;295:86-96.
23. Moriyama K, Okamoto H, Tsuda F, Mayumi M. Reduced precore transcription and enhanced core-pregenome transcription of hepatitis B virus DNA after replacement of the precore-core promoter with sequences associated with e antigen-seronegative persistent infections. Virology 1996;226:269-280.
24. Yokosuka O, Omata M, Imazeki F, Okuda K, Summers J. Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: analysis of intrahepatic replicative hepatitis B virus DNA. HEPATOLOGY 1985;5:728-734.
25. Mason WS, Cullen J, Saputelli J, Wu TT, Liu C, London WT, et al. Characterization of the antiviral effects of 2′ carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus. HEPATOLOGY 1994;19:398-411.
26. Luscombe C, Pedersen J, Uren E, Locarnini S. Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatic-viral DNA, RNA, and protein expression. HEPATOLOGY 1996;24:766-773.
27. Chen RY, Edwards R, Shaw T, Colledge D, Delaney WE, Isom H, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. HEPATOLOGY 2003;37:27-35.
28. Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J Virol 2004;78:8524-8535.
29. Addison WR, Wong WW, Fischer KP, Tyrrell DL. A quantitative competitive PCR assay for the covalently closed circular form of the duck hepatitis B virus. Antiviral Res 2000;48:27-37.
30. He ML, Wu J, Chen Y, Lin MC, Lau GK, Kung HF. A new and sensitive method for the quantification of HBV cccDNA by real-time PCR. Biochem Biophys Res Commun 2002;295:1102-1107.
31. Jun-Bin S, Zhi C, Wei-Qin N, Jun F. A quantitative method to detect HBV cccDNA by chimeric primer and real-time polymerase chain reaction. J Virol Methods 2003;112:45-52.
32. Singh M, Dicaire A, Wakil AE, Luscombe C, Sacks SL. Quantitation of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in the liver of HBV-infected patients by LightCycler real-time PCR. J Virol Methods 2004;118:159-167.
33. Wong DK, Yuen MF, Yuan H, Sum SS, Hui CK, Hall J, et al. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. HEPATOLOGY 2004;40:727-737.
34. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-1758.
35. Sung JJ, Wong ML, Bowden S, Liew CT, Hui AY, Wong VW, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005;128:1890-1897.
36. Addison WR, Walters KA, Wong WW, Wilson JS, Madej D, Jewell LD, et al. Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol 2002;76:6356-6363.
37. Wieland SF, Spangenberg HC, Thimme R, Purcell RH, Chisari FV. Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci U S A 2004;101:2129-2134.
38. Zhang YY, Zhang BH, Theele D, Litwin S, Toll E, Summers J. Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver. Proc Natl Acad Sci U S A 2003;100:12372-12377.
39. Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller DS, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001;75:311-322.
40. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
41. Su Q, Wang SF, Chang TE, Breitkreutz R, Hennig H, Takegoshi K, et al. Circulating hepatitis B virus nucleic acids in chronic infection: representation of differently polyadenylated viral transcripts during progression to nonreplicative stages. Clin Cancer Res 2001;7:2005-2015.
42. Zhang W, Hacker HJ, Tokus M, Bock T, Schroder CH. Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy. J Med Virol 2003;71:24-30.
43. Summers J, Smith PM, Horwich AL. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J Virol 1990;64:2819-2824.
44. Lenhoff RJ, Summers J. Construction of avian hepadnavirus variants with enhanced replication and cytopathicity in primary hepatocytes. J Virol 1994;68:5706-5713.